about
Healthy firms: constraints to growth among private health sector facilities in Ghana and KenyaDo people taking flu vaccines need them the most?Private sector participation and health system performance in sub-saharan AfricaPrivate sector provision of oral rehydration therapy for child diarrhea in sub-Saharan Africa.Innovation and The Welfare Effects of Public Drug Insurance.HIV-related social intolerance and risky sexual behavior in a high HIV prevalence environment.Firm-level perspectives on public sector engagement with private healthcare providers: survey evidence from Ghana and KenyaGovernment health insurance for people below poverty line in India: quasi-experimental evaluation of insurance and health outcomes.Effects of competition on the cost and quality of inpatient rehabilitation care under prospective payment.Effects of Medicare payment reform: evidence from the home health interim and prospective payment systems.Barriers to use of oral rehydration salts for child diarrhea in the private sector: evidence from India.Do Statins Reduce the Health and Health Care Costs of Obesity?Behind-the-counter statins: a silver bullet for reducing costs and increasing access?Impact of health insurance for tertiary care on postoperative outcomes and seeking care for symptoms: quasi-experimental evidence from Karnataka, India.Determinants of healthcare provider recommendations for influenza vaccinations.PEPFAR Funding Associated With An Increase In Employment Among Males in Ten Sub-Saharan African Countries.Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India: Cost-Effectiveness Analysis.Applying appropriate-use criteria to cardiac revascularisation in IndiaMARKET EVIDENCE OF MISPERCEIVED MORTALITY RISK.Market power and state costs of HIV/AIDS drugs.Test-and-treat in Los Angeles: a mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County.Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development.Health Insurance as a Two-Part Pricing ContractThe effect of prospective payment on admission and treatment policy: evidence from inpatient rehabilitation facilities.U.S. pharmaceutical policy in a global marketplace.The effect of regulation on pharmaceutical revenues: experience in nineteen countries.Employer-sponsored insurance, health care cost growth, and the economic performance of U.S. Industries.Risk selection into consumer-directed health plans: an analysis of family choices within large employers.The Affordable Care Act may increase the number of people getting tested for HIV by nearly 500,000 by 2017.HIV care providers emphasize the importance of the Ryan White Program for access to and quality of care.Association between availability of health service prices and payments for these services.Comparative performance of public and private sector delivery of BCG vaccination: evidence from Sub-Saharan Africa.Pharmaceutical advertising and Medicare Part DReply to Gonzalez-Serna et al.Does stewardship make a difference in the quality of care? Evidence from clinics and pharmacies in Kenya and Ghana.Legal status and health insurance among immigrants.Hospital Productivity: The Authors Reply.Impact of postpartum hospital-stay legislation on newborn length of stay, readmission, and mortality in California.Immigrants and the cost of medical care.US hospitals experienced substantial productivity growth during 2002-11.
P50
Q28731784-19D733A5-87D6-421D-B02A-5E7CF119FF15Q28742021-CC0F6B5D-B942-4D06-A9D1-4589B6D59D73Q28748947-2BF296DA-BA7C-4A75-BB66-1A6204248C64Q33588563-B74DD020-6C99-464F-88EF-7D84EAB56B61Q33834130-8FE36463-D3E5-41FE-BB62-B2AAE0D15984Q33893020-BA3ADEFA-93A3-4C8A-B8EF-ABB1738E16B0Q34087681-55C366D9-0FA0-4931-B1F6-4756A34D78B3Q34167865-17D2B3DB-AABE-441E-B70F-7F7A95946FF4Q34534651-BC6E5381-D0C2-4E6D-9F22-652C7C4CAEF6Q34631451-C2B60BE6-BDC5-4A9E-ACCB-9FFF36D0D8ECQ35221306-B3DB873C-9F77-43EC-BC90-5C59196CC2BDQ35812297-2CA07956-E2D2-499C-B464-61768B2FBC89Q36248047-8728AE49-43A0-4D4E-963B-2148CA6D78A3Q36472125-7F73E843-DA62-4D48-B467-6879B5C5F4D4Q36486317-771632D5-AA97-4E9D-88CD-D25ABF62C939Q36663576-93948F85-97A3-407D-B941-4219CC22B458Q36710337-A1DB47C8-412D-487E-B80B-3334FC5EF71DQ36773041-D45F6069-270B-4124-9C4F-2813D8AE36CDQ36777727-8E2A1A48-5724-4899-9AAB-B9369D98E20EQ36812965-991AA5C1-269B-42BD-B9EC-30807E1F3BBAQ36856942-1092F091-4DD7-432C-B383-43DB4F6663C9Q37014496-6C63780E-2256-4EBF-A400-C27B11F4CE64Q37119851-7D9931C6-88D9-4EBC-9FED-B283DABB1686Q37216726-10C56AC4-C2B4-441B-85BE-79589D775004Q37244987-22286C43-F480-4ED0-8F3B-2F4EA3C69AC2Q37313282-6CCA3892-DA2C-45AF-BEB7-44F8E4240DE1Q37368794-C47D1205-E22E-4822-A4FD-BF09EEC5A804Q37685519-0E1D72ED-740E-45E7-B0DD-0C32D128905AQ38192982-56C877BF-F6B8-445F-A017-4EE7AB70F752Q38192984-C80BBD8B-29A0-4891-9CE2-755F878E5ABCQ38261768-443733B3-182A-45F4-A54C-1CB0172A3E2BQ39567814-D22CD0E5-317B-4646-949E-C109BF06B964Q41869987-E4B378FD-5106-4733-83C3-961608379B4FQ43104165-56CFF4BE-D58A-41C1-AAE7-3D2575C9A6B3Q45054455-D831DB02-E420-4C86-9A12-BAE931928FAAQ45966158-5D3E6A2A-EB35-4C31-9C20-3130DDEA4291Q46067436-7D59FF7D-86C8-4F7B-8D3C-978F50A33D58Q46220285-CA6613C6-B60F-41E9-8CC7-1AD6AADF0D21Q46508461-4561CEA1-EE57-4B68-9EEE-4160570FAF79Q46690938-3315ECC3-D522-427E-AA8E-E4A25DE9F2FD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Neeraj Sood
@ast
Neeraj Sood
@en
Neeraj Sood
@es
Neeraj Sood
@nl
Neeraj Sood
@sl
type
label
Neeraj Sood
@ast
Neeraj Sood
@en
Neeraj Sood
@es
Neeraj Sood
@nl
Neeraj Sood
@sl
prefLabel
Neeraj Sood
@ast
Neeraj Sood
@en
Neeraj Sood
@es
Neeraj Sood
@nl
Neeraj Sood
@sl
P106
P1153
56425486100
7007153608
P31
P496
0000-0001-9805-213X